Emmaus Life Sciences Shares Outstanding 2006-2021 | EMMA

Emmaus Life Sciences shares outstanding from 2006 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Emmaus Life Sciences Annual Shares Outstanding
(Millions of Shares)
2020 49
2019 42
2018 37
2018 1
2017 0
2016 0
2015 0
2014 0
2013 0
2012 0
2011 0
2010 0
2009 0
2008 0
2007
2007 0
2006
Emmaus Life Sciences Quarterly Shares Outstanding
(Millions of Shares)
2021-06-30 49
2021-03-31 49
2020-12-31 49
2020-09-30 49
2020-06-30 49
2020-03-31 49
2019-12-31 42
2019-09-30 46
2019-06-30 37
2019-03-31 37
2018-12-31 1
2018-09-30 37
2018-06-30 6
2018-03-31 1
2017-12-31 1
2017-09-30
2017-06-30 0
2017-03-31 0
2016-12-31 0
2016-09-30
2016-06-30 0
2016-03-31 0
2015-12-31 0
2015-09-30
2015-06-30 0
2015-03-31 0
2014-12-31 0
2014-09-30
2014-06-30 0
2014-03-31 0
2013-12-31 0
2013-09-30
2013-06-30 0
2013-03-31 0
2012-12-31 0
2012-09-30
2012-06-30 0
2012-03-31 0
2011-12-31 0
2011-09-30
2011-06-30 0
2011-03-31 0
2010-12-31 0
2010-09-30
2010-06-30 0
2010-03-31 0
2009-12-31 0
2009-09-30
2009-06-30 0
2009-03-31 0
2008-12-31 0
2008-09-30
2008-06-30 0
2008-03-31 0
2007-12-31 0
2007-09-30
2007-06-30 0
2007-03-31 0
2006-12-31
2006-09-30 0
2006-06-30 0
2006-03-31 0
2005-09-30 0
2005-06-30 0
2005-03-31 0
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.073B $0.023B
Emmaus Life Sciences Inc. is a commercial-stage biopharmaceutical company. It is engaged in the discovery, development, marketing and sale of treatments and therapies, for rare and orphan disease categories. Emmaus Life Sciences Inc., formerly known MYnd Analytics Inc., is based in Torrance, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $128.460B 8.55
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.211B 20.68
Biohaven Pharmaceutical Holding (BHVN) United States $8.952B 0.00
Emergent Biosolutions (EBS) United States $2.717B 6.55
Arcus Biosciences (RCUS) United States $2.502B 0.00
Myovant Sciences (MYOV) United Kingdom $1.906B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.820B 0.00
Zymeworks (ZYME) Canada $1.088B 0.00
Ambrx Biopharma (AMAM) United States $0.513B 0.00
SQZ Biotechnologies (SQZ) United States $0.343B 0.00
Enzo Biochem (ENZ) United States $0.159B 15.57